Alkaloids from the entheogenic plant Peganum harmala
Daniel G. Anstis, Jessica Liyu, Emma K. Davison, Jonathan Sperry
Australian Journal of Chemistry July 17, 2023 Peer reviewed DOI: 10.1071/ch23038
Summary
Peganum harmala contains 160 isolated alkaloids, which may have unique properties for treating mood disorders. However, most of these alkaloids lack reported bioactivity, with only a few showing inhibition of monoamine oxidases and cholinesterases. No classic entheogens were found in this plant, suggesting that these alkaloids could serve as a reference for discovering new entheogens with potential therapeutic benefits.
Study at a glance
| Key finding | The majority of the 160 alkaloids isolated from Peganum harmala have no reported bioactivity. |
|---|
Abstract
Entheogenic natural products (e.g., psylocybin and dimethyltryptamine) are emerging as effective therapeutics to treat debilitating mood disorders that are unresponsive to conventional treatment. The detailed evaluation of psychotropic plants will conceivably lead to the discovery of structurally distinct entheogens that may offer improved or complementary medicinal properties to the classic entheogens. The plant Peganum harmala has a rich history in traditional medicine, with consumption inducing a host of central nervous system (CNS) symptoms, including hallucinations. Given alkaloids are uniquely capable of altering the CNS physiology owing to their ability to cross the blood–brain barrier, the natural product(s) responsible for the entheogenic properties are likely hidden in its structurally diverse alkaloid profile. Herein, an overview of the 160 alkaloids isolated from P. harmala is provided. Remarkably, bioactivity data is scarce, limited to inhibition of monoamine oxidases and cholinesterases in a few cases, with the majority having no reported bioactivity at all. As none of the classic entheogens have been detected in P. harmala, this collection of alkaloids provides a useful reference point in the search of structurally unique entheogens.